» Articles » PMID: 30115693

IFNγ PET Imaging As a Predictive Tool for Monitoring Response to Tumor Immunotherapy

Overview
Journal Cancer Res
Specialty Oncology
Date 2018 Aug 18
PMID 30115693
Citations 56
Authors
Affiliations
Soon will be listed here.
Abstract

IFNγ is an attractive target for imaging active antitumor immunity due to its function in the T-cell signaling axis. Here, we test an IFNγ immuno-PET (immunoPET) probe for its capacity to identify adaptive immunotherapy response after HER2/neu vaccination in both spontaneous salivary and orthotopic neu mouse mammary tumors. IFNγ immunoPET detected elevated cytokine levels after vaccination, which inversely correlated with tumor growth rate, an indicator of response to therapy. In a model of induced T-cell anergy where CD8 T cells infiltrate the tumor, but upregulate PD-1, IFNγ tracer uptake was equivalent to isotype control, illustrating a lack of antitumor T-cell activity. The IFNγ immunoPET tracer detected IFNγ protein sequestered on the surface of tumor cells, likely in complex with the IFNγ receptor, which may explain imaging localization of this soluble factor Collectively, we find that the activation status of cytotoxic T cells is annotated by IFNγ immunoPET, with reduced off-target binding to secondary lymphoid tissues compared with imaging total CD3 tumor-infiltrating lymphocytes. Targeting of soluble cytokines such as IFNγ by PET imaging may provide valuable noninvasive insight into the function of immune cells This study presents a novel approach to monitor therapeutic outcomes via IFNγ-targeted positron emission tomography. .

Citing Articles

Making the effect visible - OX40 targeting nanobodies for imaging of activated T cells.

Frecot D, Blaess S, Wagner T, Kaiser P, Traenkle B, Fandrich M Front Immunol. 2024; 15:1480091.

PMID: 39474429 PMC: 11518761. DOI: 10.3389/fimmu.2024.1480091.


Validation of the C-X-C chemokine receptor 3 (CXCR3) as a target for PET imaging of T cell activation.

Martin S, Wendlinger L, Zitti B, Hicham M, Postupalenko V, Marx L EJNMMI Res. 2024; 14(1):77.

PMID: 39196448 PMC: 11358572. DOI: 10.1186/s13550-024-01142-1.


Illuminating immunotherapy response via precision T cell-targeted PET imaging.

Glazer S, Kummar S, Mittra E Front Med (Lausanne). 2024; 11:1233913.

PMID: 39104861 PMC: 11298440. DOI: 10.3389/fmed.2024.1233913.


The role of CD8 PET imaging in guiding cancer immunotherapy.

Zhang J, Du B, Wang Y, Cui Y, Wang S, Zhao Y Front Immunol. 2024; 15:1428541.

PMID: 39072335 PMC: 11272484. DOI: 10.3389/fimmu.2024.1428541.


Biomarker-driven molecular imaging probes in radiotherapy.

Li H, Gong Q, Luo K Theranostics. 2024; 14(10):4127-4146.

PMID: 38994026 PMC: 11234278. DOI: 10.7150/thno.97768.


References
1.
Rashidian M, Ingram J, Dougan M, Dongre A, Whang K, LeGall C . Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells. J Exp Med. 2017; 214(8):2243-2255. PMC: 5551571. DOI: 10.1084/jem.20161950. View

2.
Chen P, Roh W, Reuben A, Cooper Z, Spencer C, Prieto P . Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov. 2016; 6(8):827-37. PMC: 5082984. DOI: 10.1158/2159-8290.CD-15-1545. View

3.
Li K, Baird M, Yang J, Jackson C, Ronchese F, Young S . Conditions for the generation of cytotoxic CD4(+) Th cells that enhance CD8(+) CTL-mediated tumor regression. Clin Transl Immunology. 2016; 5(8):e95. PMC: 5007627. DOI: 10.1038/cti.2016.46. View

4.
Natarajan A, Mayer A, Xu L, Reeves R, Gano J, Gambhir S . Novel Radiotracer for ImmunoPET Imaging of PD-1 Checkpoint Expression on Tumor Infiltrating Lymphocytes. Bioconjug Chem. 2015; 26(10):2062-9. DOI: 10.1021/acs.bioconjchem.5b00318. View

5.
Kohrt H, Tumeh P, Benson D, Bhardwaj N, Brody J, Formenti S . Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials. J Immunother Cancer. 2016; 4:15. PMC: 4791805. DOI: 10.1186/s40425-016-0118-0. View